Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Retrophin gains US rights to Thiola from Mission Pharmacal; rights in Canada later added

Executive Summary

Retrophin Inc. (rare-disease drugs) licensed US rights to Mission Pharmacal Co.’s (dermatology, women's health, urology, pediatric therapies) kidney stone treatment Thiola (tiopronin).
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Marketing-Licensing

Related Companies